Ignite Creation Date:
2024-05-05 @ 4:45 PM
Last Modification Date:
2024-10-26 @ 9:23 AM
Study NCT ID:
NCT00301093
Status:
COMPLETED
Last Update Posted:
2020-10-28
First Post:
2006-03-08
Brief Title:
Vaccine Therapy and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia
Sponsor:
Dana-Farber Cancer Institute
Organization:
Dana-Farber Cancer Institute
Study Overview
Official Title:
Vaccination for CML Patients With Persistent Disease on Imatinib Mesylate
Status:
COMPLETED
Status Verified Date:
2020-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Vaccines made from gene-modified cancer cells may help the body build an effective immune response to kill cancer cells Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth Giving vaccine therapy together with imatinib mesylate may be an effective treatment for chronic myelogenous leukemia
PURPOSE This phase I trial is studying the side effects and best dose of vaccine therapy when given together with imatinib mesylate in treating patients with chronic phase chronic myelogenous leukemia
PURPOSE This phase I trial is studying the side effects and best dose of vaccine therapy when given together with imatinib mesylate in treating patients with chronic phase chronic myelogenous leukemia
Detailed Description:
OBJECTIVES
Primary
Determine the maximum tolerated dose of GM-K562 cell vaccine when administered with imatinib mesylate in patients with persistent chronic phase chronic myelogenous leukemia in first hematologic response
Determine the safety and toxic effects of GM-K562 cell vaccination in these patients
Secondary
Determine the disease response by serial BCR-ABL quantitative polymerase chain reaction measurements in patients treated with this regimen
Determine the development of tumor immunity in patients treated with this regimen
OUTLINE This is a dose-escalation study of GM-K562
Patients continue to receive oral imatinib mesylate at the same stable dose as before study entry Patients receive GM-K562 subcutaneously on days 1 8 15 29 43 57 85 113 and 141 in the absence of disease progression or unacceptable toxicity
Cohorts of 10 patients receive escalating doses of GM-K562 until the maximum tolerated dose MTD is determined The MTD is defined as the dose preceding that at which 3 of 10 patients experience dose-limiting toxicity
After completion of study treatment patients are followed periodically for 20 years
PROJECTED ACCRUAL A total of 30 patients will be accrued for this study
Primary
Determine the maximum tolerated dose of GM-K562 cell vaccine when administered with imatinib mesylate in patients with persistent chronic phase chronic myelogenous leukemia in first hematologic response
Determine the safety and toxic effects of GM-K562 cell vaccination in these patients
Secondary
Determine the disease response by serial BCR-ABL quantitative polymerase chain reaction measurements in patients treated with this regimen
Determine the development of tumor immunity in patients treated with this regimen
OUTLINE This is a dose-escalation study of GM-K562
Patients continue to receive oral imatinib mesylate at the same stable dose as before study entry Patients receive GM-K562 subcutaneously on days 1 8 15 29 43 57 85 113 and 141 in the absence of disease progression or unacceptable toxicity
Cohorts of 10 patients receive escalating doses of GM-K562 until the maximum tolerated dose MTD is determined The MTD is defined as the dose preceding that at which 3 of 10 patients experience dose-limiting toxicity
After completion of study treatment patients are followed periodically for 20 years
PROJECTED ACCRUAL A total of 30 patients will be accrued for this study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CDR0000456445 | REGISTRY | NCI PDQ | httpsreporternihgovquickSearchP30CA006516 |
| R21CA115043 | NIH | None | None |
| P30CA006516 | NIH | None | None |